No Knives, No Suction Hoses, No Needles, No Scars

Kuala Lumpur, 29 July 2013 – From the stubborn love handles to muffin tops and troublesome inner thighs and lower arms that all of us despise, these hard to reach areas are difficult to reduce even after hours of crunches, squats and yoga sessions at the gym.

CoolSculpting®, introduced by NeoAsia late last year, brought Malaysians an innovative and effective technology that freezes away unwanted fat. This year, NeoAsia launches the CoolFit™ Applicator, an exciting addition to the CoolSculpting product line to specifically target hard to reach areas. With three additional improvements, this new applicator is known to be more efficient and effective at fat reduction.

The CoolFit™ applicator’s advanced engineering design features a flat applicator cup and larger cooling plates, enabling treatment of more areas and more patients than ever before. It complements the CoolSculpting treatment with the following enhancements:

  • Longer Cooling Plates – to maximise treatment area with 38 per cent greater cooling surface than CoolCore™
  • Flat Applicator Cup – Ideal for longer fat bulges
  • Unique Applicator Design – Easily treat hard-to-reach bulges

The new CoolFit™ Applicator allows a more precise and targeted treatment to be delivered to difficult areas with longer fat bulges like the inner thighs and upper arms.

According to Dr. Sutina Nordin, founder of En-hanze Medical Aesthetic Centre, with these new additional improvements, it allows for specialists like her to easily customise treatment plans for patients, particularly targeting areas like the inner thighs. She further highlighted, “Having worked in the aesthetics industry for more than 10 years, it is interesting to have a treatment like CoolSculpting out there, where Malaysians can now see more effective and efficient results achieved in those hard to reach areas. The three additional improvements are significant as consumers can now treat their difficult zones quickly and easily.”

CoolSculpting®, developed by ZELTIQ®, is a patented, non-invasive, clinically proven procedure to selectively reduce fat layers in problem areas using a patented cooling technology. It is a safe procedure cleared by the FDA that gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cells. This reduces bulges in treated areas of the body without harming surrounding tissue.

During the CoolSculpting procedure, a non-invasive applicator delivers precisely controlled cooling to the treatment area to specifically target underlying fat, leaving surface skin tissue unaffected. When fat cells are exposed to cold, a process of natural removal is triggered, which gradually reduces the thickness of the fat layer. The result is a visible reduction in fat bulges.

The results are dramatic. On average, patients can expect an average of 20 per cent reduction of fat in the treated areas, and patients will start to see results as soon as three (3) weeks following treatment, with the most dramatic results occurring over a period of two (2) to four (4) months in most patients.

The CoolSculpting® procedure can be carried out on both men and women. For more information on CoolSculpting, log on to www.coolsculpting.com/.

About NeoAsia (M) Sdn Bhd

Founded in 1995, NeoAsia prides itself in setting the standard for aesthetic technology consulting, sales, rentals and services. This is done by combining cutting-edge technologies with exceptional relationships and premier services that extends well beyond the sale. NeoAsia’s corporate headquarter is situated in Singapore, with distribution networks extended to Malaysia, Brunei, Cambodia and Vietnam. For more information, please visit www.neaosia.com.sg.

About ZELTIQ®

Founded in 2005, ZELTIQ®’s mission is to create differentiated, clinically proven, safe, and beneficial solutions with one goal in mind: a cooler you.Initial Cryolipolysis research and testing on patients was conducted by Drs. Dieter Manstein and R. Rox Anderson at the Wellman Center at Massachusetts General Hospital in Boston, a teaching affiliate for Harvard Medical School. This science and its potential served as the catalyst that attracted founding investors Advanced Technology Ventures (ATV) and Frazier Healthcare Ventures (FHV). The collaborative knowledge and insight of these three entities have played a significant role in ZELTIQ’s efforts to develop this groundbreaking medical technology.

← Back

For media enquiries only, please contact:

OGILVY PUBLIC RELATIONS 

Ryan Mok

+6019 657 2177 or ryan.mok@ogilvy.com